C

Cardiology Partners Clinical Research Institute | Palm Beach Gardens Office

Research site

(Unclaimed)

Location

3345 Burns Road Suites 206,305,306, Palm Beach Gardens, Florida, United States of America

Site insights

Top conditions

Top treatments

Apixaban

Empagliflozin

Lorcaserin HCl

BI 690517

Maridebart Cafraglutide

EVOLocumab

BELVIQ

Iron

BAY 2433334

Vicadrostat

Parent organization

This site is a part of Cardiology Partners Clinical Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 10 total trials

Locations recently updated

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling

Hypertension

Cardiovascular Diseases

Drug: Placebo matching Vicadrostat

Drug: Vicadrostat

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of car...

Enrolling

Overweight

Atherosclerotic Cardiovascular Disease

Drug: Maridebart Cafraglutide

Drug: Placebo

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting

Stroke

Myocardial Infarction

Drug: Evolocumab

Drug: Routine Lipid Management